The CATIE Schizophrenia Trial: Results, Impact, Controversy

REFERENCES

• Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989; 15: 81–9
   PubMed Web of Science ®Google Scholar
• Casey D E, Hansen T E. Excessive mortality and morbidity associated with schizophrenia. Medical illness and schizophrenia, J M Meyer, H A Nasrallah. American Psychiatric Press, Washington, DC 2003
   Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21–8
   PubMed Web of Science ®Google Scholar
• Stroup T S, McEvoy J P, Swartz M S, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15–31
   PubMed Web of Science ®Google Scholar
• Lieberman J A, Stroup T S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23
   PubMed Web of Science ®Google Scholar
• Jaffe A B, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J Clin Psychiatry 2003; 64: 3–6, suppl 17
   PubMedGoogle Scholar
• Stroup S, Appelbaum P, Swartz M, et al. Decision-making capacity for research participation among individuals in the CATIE Schizophrenia Trial. Schizophr Res 2005; 80: 1–8
   PubMed Web of Science ®Google Scholar
• McEvoy J P, Lieberman J A, Stroup T S, et al. for CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10
   PubMed Web of Science ®Google Scholar
• Stroup T S, Lieberman J A, McEvoy J P, et al. for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuing a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–22
   PubMed Web of Science ®Google Scholar
• Swartz M S, Wagner H R, Swanson J W, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006; 57: 1110–6
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421
   PubMed Web of Science ®Google Scholar
• Meyer J M, Nasrallah H A, McEvoy J P, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80: 9–18
   PubMed Web of Science ®Google Scholar
• Goff D C, Sullivan L M, McEvoy J P, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45–53
   PubMed Web of Science ®Google Scholar
• Basu A, Meltzer H Y. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res 2006; 86: 99–109
   PubMed Web of Science ®Google Scholar
• McEvoy J P, Meyer J M, Goff D C, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32
   PubMed Web of Science ®Google Scholar
• Nasrallah H A, Meyer J M, Goff D C, McEvoy J P, Davis S M, Stroup T S. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE Schizophrenia Trial sample at baseline. Schizophr Res 2006; 86: 15–22
   PubMed Web of Science ®Google Scholar
• Keefe R S, Bilder R M, Harvey P D, et al. Baseline neurocognitive deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology 2006; 31: 2033–46
   PubMed Web of Science ®Google Scholar
• Keefe R S, Mohs R C, Bilder R M, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003; 29: 45–55
   PubMed Web of Science ®Google Scholar
• Keefe R SE, Bilder R M, Davis S M, et al. for the CATIE Investigators and the Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64: 633–47
   PubMed Web of Science ®Google Scholar
• Harvey P D, Keefe R SE. Studies of cognitive change in patients with schizophrenia following treatment with second-generation antipsychotics. Am J Psychiatry 2001; 158: 176–84
   PubMed Web of Science ®Google Scholar
• Keefe R SE, Silva S G, Perkins D O, Lieberman J A. The effects of second-generation antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201–22
   PubMed Web of Science ®Google Scholar
• Miller D, McEvoy J P, Davis S M, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE Schizophrenia Trial. Schizophr Res 2005; 80: 33–43
   PubMed Web of Science ®Google Scholar
• Crow T J, Cross A J, Johnstone E C, Owen F, Owen D GC, Waddington J L. Abnormal involuntary moveents in schizophrenia: Are they related to the disease process or its treatment? Are they related to changes in dopamine receptors?. J Clin Psychopharmacol 1982; 2: 236–40
   Google Scholar
• Swartz M S, Wagner H R, Swanson J W, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE Study. J Nerv Ment Dis 2006; 194: 164–72
   PubMed Web of Science ®Google Scholar
• Swanson J, Swartz M, van Dorn Richard, et al. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 2006; 63: 490–9
   PubMed Web of Science ®Google Scholar
• Torrey E F. Violence and schizophrenia. Schizophr Res 2006; 88: 3–4
   PubMed Web of Science ®Google Scholar
• Rosenheck R A, Leslie D, Sindelar J, et al. for the CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080–9
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull 2003; 29: 81–93
   PubMedGoogle Scholar
• Jones P B, Barnes T R, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87
   PubMed Web of Science ®Google Scholar
• Rosenheck R A, Stroup S, Keefe R, et al. Measuring outcome priorities and incorporating preferences in mental health status assessment of people with schizophrenia. Br J Psychiatry 2005; 187: 529–36
   PubMed Web of Science ®Google Scholar
• Perlick D A, Rosenheck R A, Kaczynski R, Swartz M S, Canive J M, Lieberman J A. Components and correlates of family burden in schizophrenia. Psychiatr Serv 2006; 57: 1117–25
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Leslie D, Keefe R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006; 163: 411–7
   PubMed Web of Science ®Google Scholar
• Swartz M S, Perkins D O, Stroup T S, McEvoy J P, Nieri J M, Haak D C. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophr Bull 2003; 29: 33–43
   PubMedGoogle Scholar
• Essock S M, Covell N H, Davis S M, Stroup T S, Rosenheck R E, Lieberman J A. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163: 2090–5
   PubMed Web of Science ®Google Scholar
• Malaspina D, Harlap S, Fennig S, et al. Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry 2001; 58: 361–7
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Kopelowicz A, Buchanan R, Carpenter W. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000; 22: 303–10
   PubMed Web of Science ®Google Scholar